Goldman Sachs’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-806,480
| Closed | -$145M | – | 6949 |
|
|
2017
Q3 | $145M | Buy |
806,480
+411,200
| +104% | +$57.3M | 0.04% | 590 |
|
|
2017
Q2 | $41M | Buy |
395,280
+181,336
| +85% | +$14.8M | 0.01% | 1374 |
|
|
2017
Q1 | $16.8M | Buy |
213,944
+127,358
| +147% | +$7.88M | ﹤0.01% | 2009 |
|
|
2016
Q4 | $3.88M | Buy |
86,586
+718
| +0.8% | +$35.2K | ﹤0.01% | 3271 |
|
|
2016
Q3 | $4.8M | Buy |
85,868
+43,806
| +104% | +$2.44M | ﹤0.01% | 3079 |
|
|
2016
Q2 | $2.1M | Sell |
42,062
-30,621
| -42% | -$1.5M | ﹤0.01% | 3573 |
|
|
2016
Q1 | $3.34M | Buy |
72,683
+29,720
| +69% | +$1.44M | ﹤0.01% | 3041 |
|
|
2015
Q4 | $2.65M | Buy |
42,963
+9,180
| +27% | +$646K | ﹤0.01% | 3393 |
|
|
2015
Q3 | $1.88M | Sell |
33,783
-13,943
| -29% | -$877K | ﹤0.01% | 3859 |
|
|
2015
Q2 | $2.91M | Buy |
47,726
+40,490
| +560% | +$2.31M | ﹤0.01% | 3470 |
|
|
2015
Q1 | $417K | Buy |
+7,236
| New | +$485K | ﹤0.01% | 5325 |
|
Goldman Sachs's KITE Position: Q4 2017 in Review
Goldman Sachs sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 806,480 shares — an estimated $145M sold.
Goldman Sachs first reported a position in KITE in Q1 2015 and held it in 11 quarters. The position peaked at $145M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Goldman Sachs reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Goldman Sachs sold 806,480 Kite Pharma, Inc. shares in Q4 2017, an estimated $145M.
- Goldman Sachs first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 11 quarters.
- Goldman Sachs's Kite Pharma, Inc. position peaked at $145M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.